Skip to main content
. 2016 Apr 2;15:56. doi: 10.1186/s12933-016-0365-x

Fig. 4.

Fig. 4

Overall major adverse-cardiovascular-events free rates for ACEi and ARB users after propensity score weighting. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, MACE major adverse cardiovascular events